Difference between revisions of "Coronavirus studies"
(added recent study) |
(added on to "see also" on the top of the page) |
||
| Line 1: | Line 1: | ||
| − | <center>''See also [[Flawed coronavirus studies]]''.</center> | + | <center>''See also: [[Flawed coronavirus studies]], [[Hydroxychloroquine denial]]''.</center> |
Numerous '''coronavirus studies''' demonstrate the prophylactic and early use of [[hydroxychloroquine]] against [[COVID-19]], which are being ignored or downplayed for political reasons. | Numerous '''coronavirus studies''' demonstrate the prophylactic and early use of [[hydroxychloroquine]] against [[COVID-19]], which are being ignored or downplayed for political reasons. | ||
Revision as of 20:25, July 8, 2020
Numerous coronavirus studies demonstrate the prophylactic and early use of hydroxychloroquine against COVID-19, which are being ignored or downplayed for political reasons.
Here is a sampling of the growing list of valid studies confirming the effectiveness of hydroxychloroquine against COVID-19:
Minnesota data mining study
The incidence rate and mortality from COVID-19 was found to be lower in patients on chronic hydroxychloroquine therapy, in a large Minnesota healthcare system.
Between April 1, 2019 and March 31, 2020, the database contained 1,271,014 unique patient encounters, including a total of 2945 COVID-19 tests, of which 125 (4.24%) were positive.
Among the tests performed, 124 (4.35%) were positive for COVID-19 while not having taken hydroxychloroquine, while 96 tests were performed in patients with existing hydroxychloroquine prescriptions and only one (1.04%) was positive.
Two COVID-19 patients not on hydroxychloroquine died, while no COVID-19 patients not on hydroxychloroquine died.
Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.[1]
French study
In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."[2]
References
| |||||||||||||||||||||||||||||||||||